Strict Phosphate Control May Slow Coronary Artery Calcification in HD
Vascular calcification is the most likely mechanism underlying the association between hyperphosphatemia and mortality, according to investigators.
Hyperphosphatemia
Phosphate Binder Found to Raise Blood Pressure in Chronic Kidney Disease
Investigators found a clinically significant difference in systolic blood pressure among patients with stage 3b to 4 chronic kidney disease taking and not taking lanthanum carbonate.
Study: Controlling Bone Mineral Parameters in Advanced CKD May Up Survival
Study data illustrate the potential benefits of controlling serum phosphate, intact parathyroid hormone, and calcium levels in patients with nondialysis-dependent chronic kidney disease.
CKD-MBD Testing, Monitoring Suboptimal in Advanced CKD
In a large US study, only half of patients with stage 3, 4, and 5 had undergone PTH retesting at 12, 8, and 4.5 months, respectively, after treatment with vitamin D sterols, in line with KDIGO guidelines.
Therapeutic Advances in Kidney Failure Care Linked to Improved Survival
Study results show that mortality among hemodialysis patients declined from 2006 to 2015 compared with the general Swedish population.
Minimal Interference Found Between Phosphate Binders, Daprodustat
In a study, hemoglobin values did not differ meaningfully among daprodustat users, whether or not they also took one or more phosphate binders.
Risk of Nonspinal Fracture Increased in Moderate to Severe CKD
Fracture prevention efforts should be considered in patients with CKD of any age, according to investigators.
Tenapanor Under Review for Hyperphosphatemia in CKD
Tenapanor is a first-in-class oral medication that works by blocking the NHE3 transporter in the gastrointestinal tract.
High Serum Phosphate Concentration May Be Associated With Greater MALE Risk in Hemodialysis
Elevated serum phosphate concentration may be associated with an increased risk for major adverse limb events in patients undergoing hemodialysis.
Iron-Based Phosphate Binder Is Effective, Does Not Cause Iron Overload
A study of stable dialysis patients receiving sucroferric oxyhydroxide found no significant changes in hemoglobin, ferritin level, and transferrin saturation.
-
Loading...
-
Loading...
Next post in Anemia
